Abstract
Tuberculosis (TB) is a high-burden infectious disease, especially in low and middle-income countries. The efforts to eliminate this disease are challenged by the emergence of multidrug resistance and TB-HIV coinfection. The cumulative knowledge on pharmacokinetics/ pharmacodynamics of antituberculosis agents has recently encouraged therapeutic drug monitoring (TDM) in patient care. However, logistical problems related to conventional sampling limit the application of TDM in research-oriented institutions. Dried blood spot (DBS) compared with conventional venous blood sampling has the advantages of easier sampling, storage and transportation, thus enabling the application of TDM even in remote areas. In addition, DBS with its lower biohazardous risk can be safely performed in a high HIV prevalence area, which also tends to have a high TB burden. Another benefit of DBS sampling is that it requires a smaller blood volume than conventional sampling and is highly recommended for application in pediatric TB. A limitation of DBS is that additional considerations are required for analysis method development and validation. The accuracy of the DBS method is influenced by a number of factors that need to be thoroughly examined in method development and validation. Further, the agreement between DBS and plasma/serum concentrations is not always understood and further investigations are required.
Keywords: Dried blood spot, tuberculosis, optimization, biohazards, malabsorption, rifabutin, isoniazid, ethambutol, hemoglobin, venous plasma
Current Pharmaceutical Design
Title: Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization
Volume: 17 Issue: 27
Author(s): D. H. Vu, J. W.C. Alffenaar, P. M. Edelbroek, J. R.B.J. Brouwers and D. R.A. Uges
Affiliation:
Keywords: Dried blood spot, tuberculosis, optimization, biohazards, malabsorption, rifabutin, isoniazid, ethambutol, hemoglobin, venous plasma
Abstract: Tuberculosis (TB) is a high-burden infectious disease, especially in low and middle-income countries. The efforts to eliminate this disease are challenged by the emergence of multidrug resistance and TB-HIV coinfection. The cumulative knowledge on pharmacokinetics/ pharmacodynamics of antituberculosis agents has recently encouraged therapeutic drug monitoring (TDM) in patient care. However, logistical problems related to conventional sampling limit the application of TDM in research-oriented institutions. Dried blood spot (DBS) compared with conventional venous blood sampling has the advantages of easier sampling, storage and transportation, thus enabling the application of TDM even in remote areas. In addition, DBS with its lower biohazardous risk can be safely performed in a high HIV prevalence area, which also tends to have a high TB burden. Another benefit of DBS sampling is that it requires a smaller blood volume than conventional sampling and is highly recommended for application in pediatric TB. A limitation of DBS is that additional considerations are required for analysis method development and validation. The accuracy of the DBS method is influenced by a number of factors that need to be thoroughly examined in method development and validation. Further, the agreement between DBS and plasma/serum concentrations is not always understood and further investigations are required.
Export Options
About this article
Cite this article as:
H. Vu D., W.C. Alffenaar J., M. Edelbroek P., R.B.J. Brouwers J. and R.A. Uges D., Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470174
DOI https://dx.doi.org/10.2174/138161211797470174 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Improvements in Algorithms for Phenotype Inference: The NAT2 Example
Current Drug Metabolism 3D-QSAR Approaches in Drug Design: Perspectives to Generate Reliable CoMFA Models
Current Computer-Aided Drug Design Identification of Proteins Interacting with Human SP110 During the Process of Viral Infections
Medicinal Chemistry Meet the Editorial Board Member
Current Pharmaceutical Biotechnology Meet Our Co-Editor
Central Nervous System Agents in Medicinal Chemistry New Potential Pharmaceutical Applications of Hypericum Species
Mini-Reviews in Medicinal Chemistry Targeting Inhibition of COX-2: A Review of Patents, 2002 - 2006
Recent Patents on Inflammation & Allergy Drug Discovery Salicylanilide Ester Prodrugs as Potential Antimicrobial Agents - a Review
Current Pharmaceutical Design Biological Evaluation of Small Molecule Inhibitors of Mtb-ASADH Enzyme
Letters in Drug Design & Discovery Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio
Current Medicinal Chemistry Quinoline Derivatives: Candidate Drugs for a Class B G-Protein Coupled Receptor, the Calcitonin Gene-Related Peptide Receptor, a Cause of Migraines
CNS & Neurological Disorders - Drug Targets Failing a First Anti-TNF in RA: Does it Imply a Change in Target?
Current Rheumatology Reviews Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Aspartic Peptidases of Human Pathogenic Trypanosomatids: Perspectives and Trends for Chemotherapy
Current Medicinal Chemistry Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Advancements in Devices and Particle Engineering in Dry Powder Inhalation Technology
Current Topics in Medicinal Chemistry An Overview on Chemistry and Biological Importance of Pyrrolidinone
Current Organic Synthesis Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Complement 3 Receptor Expression in Individuals with Type 2 Diabetes
Recent Patents on Anti-Infective Drug Discovery